Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

New targets for old drugs: cardiac glycosides inhibit atrial-specific K2P3.1 (TASK-1) channels.

Schmidt C, Wiedmann F, Gaubatz AR, Ratte A, Katus HA, Thomas D.

J Pharmacol Exp Ther. 2018 Apr 11. pii: jpet.118.247692. doi: 10.1124/jpet.118.247692. [Epub ahead of print]

2.

Ion Channel Dysfunctions in Dilated Cardiomyopathy in Limb-Girdle Muscular Dystrophy.

El-Battrawy I, Zhao Z, Lan H, Li X, Yücel G, Lang S, Sattler K, Schünemann JD, Zimmermann WH, Cyganek L, Utikal J, Wieland T, Bieback K, Bauer R, Ratte A, Pribe-Wolferts R, Rapti K, Nowak D, Wittig J, Thomas D, Most P, Katus HA, Ravens U, Schmidt C, Borggrefe M, Zhou XB, Müller OJ, Akin I.

Circ Genom Precis Med. 2018 Mar;11(3):e001893. doi: 10.1161/CIRCGEN.117.001893.

PMID:
29545480
3.

Stretch-activated two-pore-domain (K2P) potassium channels in the heart: Focus on atrial fibrillation and heart failure.

Schmidt C, Wiedmann F, Kallenberger SM, Ratte A, Schulte JS, Scholz B, Müller FU, Voigt N, Zafeiriou MP, Ehrlich JR, Tochtermann U, Veres G, Ruhparwar A, Karck M, Katus HA, Thomas D.

Prog Biophys Mol Biol. 2017 Nov;130(Pt B):233-243. doi: 10.1016/j.pbiomolbio.2017.05.004. Epub 2017 May 16.

PMID:
28526353
4.

Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.

Schmidt C, Wiedmann F, Zhou XB, Heijman J, Voigt N, Ratte A, Lang S, Kallenberger SM, Campana C, Weymann A, De Simone R, Szabo G, Ruhparwar A, Kallenbach K, Karck M, Ehrlich JR, Baczkó I, Borggrefe M, Ravens U, Dobrev D, Katus HA, Thomas D.

Eur Heart J. 2017 Jun 7;38(22):1764-1774. doi: 10.1093/eurheartj/ehw559.

PMID:
28057773

Supplemental Content

Support Center